- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in subjects with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy (RT) results in an improvement of metastasis-free survival (MFS) evaluated by blinded independent central review (BICR)
Critère d'inclusion
- High- or very-high risk, localized or locally advanced prostate cancer